US20190262831A1 - High resolution spatial genomic analysis of tissues and cell aggregates - Google Patents

High resolution spatial genomic analysis of tissues and cell aggregates Download PDF

Info

Publication number
US20190262831A1
US20190262831A1 US16/342,758 US201716342758A US2019262831A1 US 20190262831 A1 US20190262831 A1 US 20190262831A1 US 201716342758 A US201716342758 A US 201716342758A US 2019262831 A1 US2019262831 A1 US 2019262831A1
Authority
US
United States
Prior art keywords
sample
array
amplification
substrate
cellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US16/342,758
Other languages
English (en)
Inventor
Jason A.A. West
Kyle Hukari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioskryb Genomics Inc
Original Assignee
Lociomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lociomics Corp filed Critical Lociomics Corp
Priority to US16/342,758 priority Critical patent/US20190262831A1/en
Assigned to Lociomics Corporation reassignment Lociomics Corporation ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HUKARI, Kyle, WEST, JASON A.A.
Publication of US20190262831A1 publication Critical patent/US20190262831A1/en
Assigned to BioSkryb Genomics, Inc. reassignment BioSkryb Genomics, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Lociomics Corporation
Pending legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502715—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502753—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B20/00—Methods specially adapted for identifying library members
    • C40B20/02—Identifying library members by their fixed physical location on a support or substrate
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B20/00—Methods specially adapted for identifying library members
    • C40B20/04—Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/02—Identification, exchange or storage of information
    • B01L2300/021—Identification, e.g. bar codes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0627—Sensor or part of a sensor is integrated
    • B01L2300/0645—Electrodes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0681—Filter
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0819—Microarrays; Biochips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0887—Laminated structure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/18—Means for temperature control
    • B01L2300/1805—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks
    • B01L2300/1827—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks using resistive heater
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0415—Moving fluids with specific forces or mechanical means specific forces electrical forces, e.g. electrokinetic
    • B01L2400/0421—Moving fluids with specific forces or mechanical means specific forces electrical forces, e.g. electrokinetic electrophoretic flow
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L7/00—Heating or cooling apparatus; Heat insulating devices
    • B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
    • B01L7/525—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples with physical movement of samples between temperature zones

Definitions

  • RNA transcriptome mRNA (transcriptome) and DNA (genome)
  • SBS sequencing by synthesis
  • NGS next generation sequencing
  • FFPE formalin-fixed paraffin embedded
  • Key advantages of the disclosed technology include, e.g., the ability to provide highly flexible, selectable regions of high resolution analysis of the expressed genes or proteins as well as the detection of genetic modifications that have occurred in a cell or a group of cells.
  • genes present a specific cell within a tissue section are first transferred to a surface, which may be accomplished by a variety of methods.
  • This surface may include a spatially specific arrangement of oligonucleotides, or barcodes, so to allow recapitulation of the sequences with the original tissue organization.
  • Genetic signatures that are transferred can then be processed, tagged, amplified, and otherwise processed so to allow all genes or gene modifications in a specific location to be identified using methods such as NGS, for example. Because these genes are identified using a specific sequence in a specific position on the transfer array surface, the location of a specific transcript can be mapped back to the original location on the array and subsequently to the location or position in the tissue section.
  • the disclosed technology is capable of performing sample preparation for the massively paralleled multiplexed detection and identification of a specific set of transcripts in a specific cell in a precise location of a tissue or multiple cell sample.
  • the present technology provides, e.g., systems including a variety of integrated components, including reagent delivery and lysing apparatus, fluid manipulation componentry comprising a series of pumps and valves, thermal control regions, electrical current control, and plurality of barcoded oligonucleotides for resolving the location specificity of specific transcript.
  • the present invention provides the ability to essentially detect all expressed genes, gene modifications, and proteins in an aggregation of cells by a variety of methods using an integrated sample preparation and discrete barcode array device.
  • the present disclosure provides systems, comprising: a plurality of base polynucleotides disposed on an amplification substrate; an optionally porous cellular support substrate, the optionally porous cellular support substrate and the amplification substrate defining a chamber therebetween; an inlet, the inlet optionally comprising an aperture formed in the cover, the inlet optionally placing the optionally porous cellular support substrate into fluid communication with the environment exterior to the optionally porous cellular support substrate.
  • methods comprising: liberating nucleic acids from a cellular sample affixed to an optionally porous cellular support substrate, the cellular sample overlying a plurality of amplification primers; translocating the nucleic acids in a direction perpendicular from the optionally porous cellular support substrate under such conditions that the nucleic acids hybridize to at least some of the plurality of amplification primers, the liberated nucleic acids optionally being communicated in the direction of the plurality of amplification primers through the pores of a porous material; amplifying the nucleic acids so as to give rise to amplification products; and associating at least some of the amplification products with locations within the cellular sample.
  • sample preparation systems for high resolution spatial genetic analysis, comprising: (a) a sample preparation module material capable of attaching a cellular sample to an optionally porous cellular support substrate that allows imaging of the tissue or cell aggregate or tissue section sample on one side, and provides the ability to deliver reagents to the sample; (b) a sample preparation module material that allows chemical fixation of a cellular sample to occur on the surface of the optionally porous cellular support substrate; (c) a sample preparation module that is chemically inert to non-polar solvents; (d) a sample preparation module capable of treating the cellular sample treated with reagents to label proteins with nucleic acid sequenced tagged antibodies, aptamers or any other ligand to bind to a specific protein with a cell in the sample; (e) a device capable of imaging of the cellular sample in close proximity to an array of oligonucleotides to coordinate the tissue sample location with each oligonucleotide element on the array; (f) a sample preparation module that seals
  • fluidic devices to perform high resolution spatial genomic analysis comprising: a sample preparation module, a series of fluidic channels and an array of oligonucleotides disposed on a conductive surface within the device so as to allow for one or more of sample addition, fixation, paraffin removal, incubation, sample imaging, active control target of sample nucleic acid templates, and multistep molecular biology reactions to effect sample preparation, hybridization, reverse transcription and first strand cDNA synthesis of sample templates with the device.
  • Also provided are methods for spatially resolving protein and/or nucleic acids from biological samples comprising the steps of: mounting a sample to a porous surface; hydrating the sample; placing the sample into fluid communication with a second surface that having a barcode disposed thereon and the second surface being electrically conductive; obtaining positional information regarding the sample relative to the barcode array; digesting the sample so as to release nucleic acid targets; translocating the targets to the barcode array of the second surface so as to effect hybridization; effecting sequencing of the hybridized targets; correlating results of the sequencing so as to positionally resolve the location within the sample from which one or more targets originated.
  • the device and associated method enable the preparation of a tissue section or cell aggregate sample to be affixed to the sample preparation module, then imaged and processed to allow release of the template nucleic acids. Said template nucleic acids are then transferred through an active process which captures the sample nucleic acids in a spatially specific manner that is coordinated with the original location of the templates in the tissue sample.
  • the templates can then be copied through either reverse transcription and/or the polymerase chain reaction to enable amplification of the template copies.
  • the resultant barcoded cDNA molecules can then be released from the oligonucleotide array to further prepare the sample for sequencing analysis.
  • the detected oligonucleotide sequences arising from either RNA, DNA or proteins in the tissue are then recombined with the original image to provide a spatial genomic map of the expressed genes, gene modifications or proteins in each cell, or a specific grouping of cells in the tissue section or cell aggregate sample.
  • the systems and assay processes described herein can be performed in a completely automated fashion. The disclosed systems are robust, simple to use, and address the goals of the medical diagnostic community to provide improved therapeutic decision making for patient care and therapy.
  • FIG. 1 is a top perspective of an embodiment of the sample preparation and analysis system of the present invention.
  • FIG. 2 is a top perspective of an embodiment of the sample preparation and analysis system of the present invention that shows the layout of the internal components.
  • FIG. 3 provides an exemplary embodiment of a single barcoded oligonucleotide that is hybridized to a specific group of oligonucleotides deposited on the array surface that is attached to a surface which contains a conductive layer.
  • This barcode primer oligonucleotide contains various regions: (AC1) an array complement sequence, an enrichment primer sequence (Ed), a regional barcode sequence (BC1), a probe specific barcode sequences (BC2), a unique-molecular identifier (UMI) which is a random sequence placed into an individual oligonucleotide, and an extension primer (EP1) which acts as a primer to perform the cDNA first strand synthesis.
  • AC1 an array complement sequence
  • Ed enrichment primer sequence
  • BC1 enrichment primer sequence
  • BC2 probe specific barcode sequences
  • UMI unique-molecular identifier
  • EP1 extension primer
  • barcoded oligonucleotide is illustrative of only a single barcoded oligonucleotide and that other barcoded oligonucleotides may include sequences (e.g., Ac2, Ec2, Bc5, Bc6, EP2, and a different UMI).
  • FIG. 4 is an embodiment of the barcoding structure of the oligonucleotide array.
  • the array structure using two distinct barcode sequences in each oligonucleotide allows identification of each individual barcode in addition to a shared barcode that creates a regional sequence for a group of individual barcoded oligonucleotides.
  • a given region of a sample substrate may, upon magnification, provide a set of samples, which set may include subsets that include BC2 and BC1 oligonucleotide barcodes, a subset of samples that includes BC2 and BC3 barcode oligonucleotides, a subset that includes BC2 and BC2 (twice) oligonucleotide barcodes, and a subset that includes BC2 and BC4 oligonucleotide barcodes.
  • Sub-region of the BC2-1 set (second image from top of FIG. 4 ) provides that the sub-region may include Sequence A, Sequence B, and Sequence C of interest as shown. As shown, each of these three sequences may include different BC barcode oligonucleotide identifiers. Further examination (top image in FIG. 4 ) provides that different members of the Sequence B sub-region may in turn have different UMIs associated with them.
  • FIG. 5 is a tissue mounting device allowing attachment of a tissue section or cell aggregate on the surface of a porous material which allows reagent delivery and contact of sample with the barcode array.
  • FIG. 6 demonstrates a process for assembling a tissue section on the mounting device, the mating of the mounted tissue to the array, the digestion of the proteinaceous or non-target materials and hybridization of the released target nucleic acids on the barcode array surface. As shown in the FIG., one may image the tissue to determine precisely which region of the tissue overlies which region of the oligonucleotide array.
  • FIG. 7 is a perspective embodiment of the device which demonstrates how the sample templates are actively migrated to the array surface.
  • the device contains two electrical conductive input/outputs where the sample can be contacted by two electrodes, one where the fluid may be contacted by an electrode, and second a conductive surface which contains the oligonucleotide array.
  • the figure demonstrates how the electrical current is directed from the sample region to the array surface to enable active control of the hybridization of the sample templated with the array of oligonucleotide primer elements.
  • FIG. 8 demonstrates the process in which the high resolution and tiled barcode array is assembled; the target analytes hybridize the extension of a barcoded primer and release of the resultant first strand DNA molecule.
  • FIG. 9 is an example of a nucleic acid hybridization and processing that results in sequencing-ready library of molecules for NGS analysis.
  • This library may include information regarding, e.g., the spatial location of the cell from which certain nucleic acids were liberated.
  • the library includes all nucleic acid sequences that were transferred and copied during the preparation of the sample.
  • Nucleic acid sequences may consist of RNA (either mRNA, rRNA, or tRNA), DNA, or oligonucleotides that are linked to antibody.
  • Antibody linked oligonucleotides for example, are used to define the presence of specific protein in the tissue sample. Using multiple antibodies (e.g., up to several thousand) can allow delineation of the proteomic signature of each of the cells in the sample.
  • the spatial location of each (RNA) transcript, DNA sequence or antibody that was present in the cell can be mapped back to the original image of the cell sample.
  • the genomic and proteomic signature of each cell in the sample can be coordinated with the morphology of the cell.
  • This information is particularly helpful in understanding the resulting phenotype of a cell which results from its underlying genomic and proteomic structure.
  • the disclosed approach can assist in understanding why certain cells respond to therapy, while others are resistant.
  • the system can allow the understanding of why certain immune cells within a tumor are inactive (not killing the tumor), while others are active killing cells, which is the current basis of much of the immun-onocolgy studies.
  • a virgin polycarbonate includes mixtures of two or more virgin polycarbonates.
  • a filler includes mixtures of fillers.
  • Ranges can be expressed herein as from one particular value, and/or to another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. For example, a range of “1 to 10” includes all intermediate values, e.g., 3, 5.56, and 7.3. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
  • the terms “about” and “at or about” mean that the amount or value in question can be the value designated some other value approximately or about the same. It is generally understood, as used herein, that it is the nominal value indicated +/ ⁇ 10% a variation unless otherwise indicated or inferred. For example, “about 10” encompasses the range from 9 to 11, including 10. The term is intended to convey that similar values promote equivalent results or effects recited in the claims. That is, it is understood that amounts, sizes, formulations, parameters, and other quantities and characteristics are not and need not be exact, but can be approximate and/or larger or smaller, as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors known to those of skill in the art.
  • an amount, size, formulation, parameter or other quantity or characteristic is “about” or “approximate” whether or not expressly stated to be such. It is understood that where “about” is used before a quantitative value, the parameter also includes the specific quantitative value itself, unless specifically stated otherwise.
  • the terms “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
  • the phrase “optionally substituted alkyl” means that the alkyl group can or cannot be substituted and that the description includes both substituted and unsubstituted alkyl groups.
  • an “effective amount” refers to an amount that is sufficient to achieve the desired modification of a physical property of the composition or material.
  • an “effective amount” of a recycled polycarbonate blend refers to an amount that is sufficient to achieve the desired improvement in the property modulated by the formulation component, e.g. splaying, under applicable test conditions and without adversely affecting other specified properties.
  • the specific level in terms of wt % in a composition required as an effective amount will depend upon a variety of factors including the amount and type of recycled polycarbonate blend, amount and type of virgin polycarbonate polymer compositions, amount and type of impact modifier compositions, including virgin and recycled impact modifiers, and end use of the article made using the composition.
  • compositions of the invention Disclosed are the components useful in preparing the compositions of the invention as well as the compositions themselves to be used within the methods disclosed herein.
  • these and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds cannot be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular compound is disclosed and discussed and a number of modifications that can be made to a number of molecules including the compounds are discussed, specifically contemplated is each and every combination and permutation of the compound and the modifications that are possible unless specifically indicated to the contrary.
  • X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.
  • a weight percent (“wt %”) of a component is based on the total weight of the formulation or composition in which the component is included. For example if a particular element or component in a composition or article is said to have 8% by weight, it is understood that this percentage is relative to a total compositional percentage of 100% by weight.
  • Fluidic componentry and methods are used to perform ultra-high density analysis of biologics associated in a spatially specific manner in a tissue or cell aggregate sample.
  • Improved systems and methods that integrate an ultra-high density, specific and sensitive assay scheme into a robust front-end sample preparation is presently needed.
  • imaging systems and sample preparation methods are needed that enable the operator to perform an analysis in a three-step process: (1) affix the sample; (2) prepare the sample and (3) process the sample in an automated fashion.
  • the information reported should permit high consequence decisions to be made, demanding that the system's assay be specific and give correct prognostic information.
  • the disclosed technology enables hybridization, through active methods, of a sample template with an array of oligonucleotides to provide a complimentary base pair of a template and a primer.
  • methods are disclosed to combine a sample template molecule with a primer through complimentary base pairing of DNA or RNA to maintain the location of this genetic material in a sample. Similar to creating a copy of an image, the nucleic acids from the sample are combined with an oligonucleotide, a primer, so as to create an image of all genes and gene modifications in a specific location, a cell, within a tissue sample.
  • the disclosed technology provides the ability to barcode each gene or genetic element in a given cell in a spatially specific manner. This technology further allows the amplification of each of the barcoded genetic sequences to allow preparation of the sample for sequencing analysis. In this way, each gene of each cell can be identified and mapped back to the original location within the sample, using the spatially defined barcode oligonucleotide.
  • an apparatus that allows contact of the sample with an array of spatially defined oligonucleotides to bring the sample into contact with this array.
  • the apparatus allows the preparation of the sample to enable the hybridization through complimentary base pairing of a nucleotide sequence in the sample with a barcode oligonucleotide present on the array surface.
  • a sample include a FFPE tissue sample, a cell aggregate, or cell smear or a frozen fixed section of tissue.
  • Suitable examples of the array of barcodes include a high-density microarray (e.g., having more than 3000 spots), or an array of nucleotide sequences deposited upon a generally planar surface.
  • the apparatus allows imaging of the sample in a location-specific manner, which may be performed in combination with the oligonucleotide array to create an image map that provides coordination of the location of the sample with the array or oligonucleotide sequences deposited upon the microarray.
  • imaging of the sample in a location-specific manner, which may be performed in combination with the oligonucleotide array to create an image map that provides coordination of the location of the sample with the array or oligonucleotide sequences deposited upon the microarray.
  • each and every cell in a specific location of the tissue or the entire section of tissue can be analyzed.
  • Using the disclosed methods allows the selection of critical region for analysis and allows rejection of areas that are either not populated by cells or of areas that are not of interest.
  • Pathologists routinely use their training in histopathology to determine the state of a group of cells in a normal or abnormally functioning tissue sample. They simply understand what appears normal and what does not.
  • ISH In Situ Hybridization
  • the disclosed technology allows the association of the histological attributes with the genomic structure by creating an image map of the tissue in combination with transfer of the genetic material to a surface that can be spatially resolved and used to prepare the transferred macromolecules for analysis. In this way, the entire genetic code can be further analyzed and mapped back to the cells or regions where these macromolecules resided in the tissue sample or cell aggregate sample.
  • tissue This is accomplished by mounting the tissue to a transparent media, such as glass or fused silica, to image this section or cell aggregate and provide the ability to either transfer the macromolecules from the tissue to a surface or alternatively transfer the spatially resolved molecular identifiers (i.e. barcoded oligonucleotides) into the tissue.
  • a transparent media such as glass or fused silica
  • the spatially resolved molecular identifiers i.e. barcoded oligonucleotides
  • Suitable samples that can be analyzed by the methods disclosed herein include, but are not limited to, cell aggregates, cell smears, tissue samples, and liquid samples such as blood. In many cases these tissue samples are preserved using fixatives including but not limited to para-formaldehyde, glutaraldehyde, and formalin, which create chemical cross links in the proteinaceous tissue. These tissues are further processed to preserve the structure of the tissue in paraffin-embedded blocks or cubes, which allow the pathologist to create thin sections of the material for histological examination.
  • FFPE Formalin-Fixed Paraffin-Embedded
  • This process may be followed by digestion of the sample with a protein digestive enzyme such as Protease or Proteinase K. This digestion removes the cross-linked proteins from the sample by cleaving the peptide bonds that provide the sample its structure.
  • This process results in a sample that contains a soluble fraction in solution which contains cleaved peptides and liberated nucleic acids, including, depending on the process, intact DNA and RNA.
  • This solution is then further purified to remove the soluble protein fraction to yield a highly enriched sample of nucleic acid.
  • this process includes digestion of DNA and/or RNA depending on the experimental procedures.
  • a drawback of this procedure is the loss of the relationship of the location of nucleic acids in the actual cells and the position of these cells within the tissue sample.
  • the majority of procedures to isolate nucleic acids utilize a similar process to purify the nucleic acids for downstream analytical techniques, including real time PCR, and sequencing applications.
  • the processes in almost all cases result in the loss of the relationship of the nucleic acids with the cells in which this DNA originated.
  • mRNA gene transcripts
  • DNA gene modifications
  • the single cell techniques rely on creating a suspension of live cells to allow compartmentalization of the cell necessary for analysis of the single cell. These techniques include microfluidic partitioning of the single cells or compartmentalization of the cell in a droplet to allow amplification and detection of the intracellular macromolecules, such as RNA [4-7, 12, 13].
  • the tissue is mounted upon a substrate that allows viewing using standard microscopy techniques that allow imaging of the tissue in relationship to various fiducial markers that provide the specific position of the tissue in relationship to a series of oligonucleotides that contain specific sequences which are orientated with a specific position within an ultra-high dense array of oligonucleotide barcodes.
  • a first step in preparing the tissue or cell sample for this imaging step is the mounting of the sample upon a substrate that allows the sample to be affixed to the substrate.
  • This substrate can take many forms. The material selection of this substrate will depend on the type of sample and the steps required to prepare contacting the sample to the oligonucleotide barcode array. In some cases, the substrate will be porous to allow both tissue adherence to the surface of the substrate combined with the ability to perform downstream steps that include delivering reagents through this substrate to the tissue sample or cell aggregate sample.
  • the substrate may be non-porous where the oligonucleotide array can be configured to dissolve into the tissue sample.
  • the critical step is affixing the sample to a semi-rigid material to allow imaging of sample in context of the barcode array.
  • Material selection of the substrate used to affix the sample will also depend on the solvents required to prepare the sample for contact with the barcode array.
  • an FFPE sample that requires paraffin material removal will require a substrate which is inert to the effects of the solvent.
  • examples of such materials include borosilicate glass, fused silica, PFTE, or other material that is inert to the solvents typically used to remove paraffin, such as toluene, or chloroethylenes, or any other highly non-polar solvents used for paraffin dissolution.
  • samples such as smears, cell aggregates, or single cell suspensions that do not require paraffin embedding and therefore do not require solvent based removal of the paraffin, can be mounted on substrate materials including thermoplastic polymers and plastics, in the steps required to prepare the samples for contact and transfer of the nucleic acids from the sample to the barcode array.
  • tissue sample is sectioned from an FFPE sample it is typically shaved from the surface of a paraffin block, e.g., in a thickness of from about 4 to about 20 microns. This section is then most often placed in a water bath to allow softening of the paraffin and allow the tissue to return to its nominal arrangement (i.e., planar) or structure. This results as the tissue section has less density than the water in the bath so it floats on the surface, which is flat. After several minutes in the bath, tissue sample is usually transferred to a planar substrate, such as a borosilicate glass slide where it is allowed to dry.
  • a planar substrate such as a borosilicate glass slide where it is allowed to dry.
  • the sample that contains both a paraffin layer and the fixed tissue is then baked for a period of time at temperatures typically below 100 deg. C. and above 30 deg. C., most commonly around 65-70 deg. C. This process typically facilitates the adherence of the tissue sample to the substrate.
  • a cell sample such as a smear or a cell aggregate
  • Alternative methods of affixing a cell sample may include the application of an alcohol such as methanol, isopropyl alcohol or ethanol to assist in the adherence of the tissue or cell sample to the substrate. This step may be conducted when the sample is still wet to prevent shrinking of the cells that are desired to be imaged for histopathology.
  • an alcohol such as methanol, isopropyl alcohol or ethanol
  • This step may be conducted when the sample is still wet to prevent shrinking of the cells that are desired to be imaged for histopathology.
  • a tissue sample can be affixed to a porous substrate, provided the material allows adherence of the tissue sample to the substrate.
  • a non-porous material can be used to affix the sample.
  • the contact of the sample with the barcode array can occur between two non-porous structures or a combination of non-porous with porous substrates. The selection of this combination is dependent on the steps required to prepare the tissue to contact with the device to allow complimentary base pairing of the genetic material in the sample to the array of barcodes that are present on the array surface, as shown in FIG. 5 .
  • the image map of the tissue is suitably created with appropriate resolution to determine the sub cellular structure of each cell in the tissue.
  • image resolution can be achieved using a variety of microscope objectives in combination with a light microscope which has at least one or several wavelengths of light that can be detected. Typical resolution can be achieved using objectives which can detect and resolve features of about 20 microns or less.
  • images are acquired at a higher resolution and subsequently stitched or combined to create a tiled map of the tissue section.
  • Higher-power objectives such as 4, 10, 20, 40, 60, 100 ⁇ may be further employed provided they have appropriate working distance from the sample.
  • fiducial markers that are arranged in the barcode array provide the location of a cell in reference or provide a direct relationship location of the barcode in reference to a cell in the tissue sample or cell aggregate sample, e.g., FIG. 5 .
  • analytes of interest may be liberated from the tissue sample or cell aggregate sample to allow hybridization through complimentary base pairing with the barcoded oligonucleotides placed upon the array surface.
  • the tissue is prepared to limit the diffusion of the analytes to off target locations.
  • the mounted tissue that has been processed to remove any interfering substances, e.g., paraffin, is placed upon the array surface as an intact tissue sample.
  • the sample Once assembled into the device (e.g., FIG. 5 ), the sample must be processed to allow liberation of the intact genetic material that is maintained in the ultra-structure of the cell by protein crosslinks formed during the fixation of the sample. After imaging within the device containing the array of barcoded oligonucleotides, the sample can then be digested to allow the liberation of the genetic material within the sample (e.g., FIG. 5 ).
  • a number of methods may be employed to remove these chemical crosslinks within the tissue sample.
  • One method commonly used to digest a proteinaceous sample is the use of serine proteolytic enzymes.
  • the use of these enzymes as opposed to simply permeabilizing the tissue sample of cells allows, in the disclosed embodiment, the ability to perform analysis of RNA transcripts, DNA fragments, as well as proteins using sequenced tagged protein binding reagents.
  • these methods can be used to release the target molecules from the sample to allow for hybridization of the sample templates with the array of barcoded oligonucleotides.
  • these solution based reactions include at least one proteolytic enzyme such as proteinase K or Protease, a detergent, such as Triton X-100TM, sodium dodecylsulfate, or sarcosine, and optionally contains a chaotropic reagent such as guanidine thiocyanate or hydrochloride and a buffer to maintain neutral pH such as sodium phosphate [14, 15].
  • the reactants in solution act in concert to cleave the peptide bonds between the amino acids of the proteins and disassociate the cleaved proteins.
  • TEAC tetraethyl ammonium chloride
  • TMAC Tetramethylammonium chloride
  • the oligonucleotide may include several sections, an enrichment primer sequence, a 1st barcode sequence which identifies where the oligonucleotide was deposited within the array and a 2nd barcode sequence and, a random sequence to assess the uniformity of amplification [16, 17], and finally a template primer sequence that facilitates hybridization to the template sequence which can be used with the combination of an RNA or DNA polymerase to make a complimentary copy though extension of the primer when hybridized to the template sequence.
  • an array complementary sequence is included in the oligonucleotide, which in some embodiments may be used to locate oligonucleotide in a specific position on the array, e.g., FIG. 2 .
  • One method to allow spatial genomic analysis is to contact the sample which resides on a surface that is placed in direct contact with second surface that contains the oligonucleotide array. It may be preferable to maintain a static, no flow environment so as to limit diffusion of either the template or the oligonucleotide primer, thereby maintaining the locational specificity of the complimentary base paired template and oligonucleotide primer hybrid.
  • the distance from the sample to the high-density oligonucleotide array is minimized. It is also preferable to control the migration; while the diffusion distance and time required to create the complimentary base paired template and oligonucleotide primer hybrid is then minimized, active steps may be used to provide high resolution mapping of the genomic sequences in the tissue specimen. Once this hybrid pair is combined (and provided the pair is not separated during subsequent steps), the location of the template arising from the cell of interest can be identified by the barcode sequence in the primer in combination with the original location of the barcode oligonucleotide on the array.
  • the sample is placed upon a porous substrate.
  • reagents that promote the release of the sample template can be communicated through the membrane.
  • the diffusion through the porous layer of the proteolytic enzymes or reagents that render the sample permeable allow the release of the sample template from the surface bound porous material, which is in contact with the array of oligonucleotide primer complex on the array surface (e.g., FIG. 5 ).
  • one part of the oligonucleotide complex is covalently attached to the array, while a second oligonucleotide is complimentary base-paired to the first covalently surface bound oligonucleotide, and then the second oligonucleotide, upon contacting the tissue, allows for complimentary base pairing with the template from the sample (e.g., FIG. 8 ).
  • the templates are liberated from the sample and diffuse out of the surface bound tissue. Due to Brownian motion of the released sample template, these nucleic acid sequences can migrate in the opposite or adjacent directions from oligonucleotides upon the array surface. This random motion may result in a loss of the resolution of the spatial nature of the genomic expression.
  • an active force is applied that minimizes off target complimentary base pairing events.
  • the sample template is conducted from the tissue location to array surface under an electrophoretic applied force, though other forces besides electrophoretic forces are suitable.
  • the sample is surrounded by appropriate aqueous solvent, so that charged molecules such as nucleic acids are actively moved from the sample to the array surface.
  • This may be accomplished by creating an electrical potential between two poles that surround the sample and the oligonucleotide array. As one example, on electrical pole may be located above the sample and one pole is located beneath the array surface ( FIG. 7 ).
  • electrical pole may be located above the sample and one pole is located beneath the array surface ( FIG. 7 ).
  • electrical current charged molecules will migrate from the sample to the target oligonucleotides complex that is covalently linked to array surface.
  • This uniform electrical field promotes efficient movement, overcoming Brownian motion, to conduct the sample template from the affixed tissue sample to the array surface, which increases the resolution of the spatially derived genomic information located in the sample.
  • the active control of the migration of the sample template to the array provides enhanced spatial resolution of genomic elements within the tissue sample.
  • both the first substrate which the sample is affixed to and second substrate which the oligonucleotide array is attached to are porous. Upon conducting the reagents through the first substrate, the released templates are conducted by fluid motion to the second porous substrate where the surface-bound oligonucleotides are located.
  • one feature of the disclosed technology that provides high resolution spatial genomic analysis is controlling this migration and providing a high resolution array of oligonucleotides to maintain locational specificity of the sample template within the tissue sample.
  • a second step may be employed to remove unwanted interfering substances by washing the array surface.
  • a second reaction is employed to create a complimentary copy of the template, using a RNA- or DNA-dependent DNA polymerase such as a reverse transcriptase or DNA polymerase.
  • This first-strand cDNA synthesis reaction allows the incorporation of one or several location-specific barcodes and also of the enrichment primer into the complimentary copy of the template sequence ( FIG. 8 ).
  • one or more templates can be copied.
  • a sequence that is specific for a given gene can be used. In this way, all cells within the tissue may be analyzed for the presence of one gene.
  • a series of sequences can be used, using a common barcode, in each position of the array.
  • the primer structure of the oligonucleotide may be common to all expressed genes, for example eukaryotic mRNA that contains a polyA tail.
  • the primer element in the oligonucleotide barcode will contain an oligo dT sequence that will hybridize to all sequences that contain a polyA tail or sequence.
  • RNA molecules arising from a cell of interest can be processed to create a first strand cDNA molecule which contains a sequence of a gene of interest in combination with the elements present in the oligonucleotide primer, such as the barcode sequence and the enrichment primer element.
  • ultrahigh spatial analysis may require several general steps, which steps may include, e.g., 1) sample pretreatment, such the removal of paraffin, 2) sample imaging, where the sample is imaged while in close proximity to the high density oligoarray, 3) release and hybridization of the sample templates to the high density array, using for example permeabilization reagents such as detergents, proteolytic enzymes nucleases, 4) removal of debris after the permeabiliztion and hybridization step, 5) creation of the first strand copy of the template primer complex, 6) harvest of the resulting first strand copy and 7) attachment of the 3′ amplification sequence to the complimentary first strand product.
  • steps may include, e.g., 1) sample pretreatment, such the removal of paraffin, 2) sample imaging, where the sample is imaged while in close proximity to the high density oligoarray, 3) release and hybridization of the sample templates to the high density array, using for example permeabilization reagents such as detergents, proteolytic enzymes nucleases, 4) removal of
  • the first step is the creation of the complimentary copy of the template.
  • This may be accomplished by combining this sample template:primer pair with a reaction mix that contains a number of substrates including nucleotides, a buffer, such as Tris-EDTA, a polymerase and a salt typically magnesium chloride.
  • Additives are often used to stabilize various base pairing combinations, such as betaine, TEAC, TMAC, or trehalose to augment the activity of the enzyme and often contain a blocking reagent such as bovine serum albumin (BSA) to limit the amount of nonspecific absorption of the enzyme in the reaction vessel.
  • BSA bovine serum albumin
  • target molecule of the sample template is an RNA species
  • an RNA dependent DNA polymerase is employed to perform reverse transcription reaction, one where a RNA molecule is copied, resulting in a first strand cDNA molecule which is an exact complimentary match of the RNA template ( FIG. 9 ).
  • RNA dependent DNA polymerase Several types of enzymes can be employed to perform this reverse transcription, including but not limited to Reverse Transcriptase M-MuLV, Moloney Murine Leukemia Virus, Reverse Transcriptase, AMV from avian myeloblastosis virus, Tth DNA Polymerase which is recombinant enzyme with both intrinsic transcriptase and thermostable DNA polymerase activity [18, 19].
  • the reaction mix may contain an inhibitor of the proteolytic enzymes.
  • an adaptor sequence is added to the 3′ end of the complimentary first strand cDNA.
  • an adaptor sequence is added to the 3′ end of the complimentary first strand cDNA.
  • a template switch process where an additional oligonucleotide is used to serve as a template to the primer molecule that is being extended.
  • This adaptor sequence can then be used as a primer, optimally the same primer sequence as the enrichment primer sequence to amplify the cDNA sample.
  • the template can then be amplified using either a common enrichment primer or a combination of primers.
  • the reaction is then thermal cycled to perform a polymerase chain reaction using a thermal stable DNA dependent DNA polymerase. Selection of enzymes is important for this stage of the reaction as the templates have a variable length in some cases up to 10 kbases. Enzymes that can be used to perform this reaction include but are not limited to SeqAMP, BST, and klenTaq enzymes.
  • Isothermal amplification techniques may be further employed to amplify the resulting first strand cDNA.
  • An example of such reaction is the recombinase amplification reaction [31].
  • Isothermal methods offer the further advantage that they can be conducted on the array surface as they use temperatures in the range of 37-42 deg. C.
  • One method of creating the enrichment primer on both the 3′ and 5′ end of the molecule is to use the template switching property of viral RNA dependent DNA polymerases [20].
  • This method uses an oligonucleotide that serves as the template towards the 3′ end of the transcript cDNA complimentary copy being created during the reverse transcription reaction.
  • the polymerase switches the template, using and RNA dependent DNA dependent DNA polymerase and a template switch oligonucleotide and creates a complimentary copy of this oligonucleotide at the end of the molecule.
  • the output of this reaction is a cDNA that has amplification primer at both 3′ and 5′ encoded into the ends of the molecule, enabling PCR amplification of the synthesized cDNA.
  • RNA:DNA hybrid Another method of encoding the reverse primer into the 3′ end of the complimentary cDNA copy is the use of ligation in the RNA:DNA hybrid [21].
  • a restriction enzyme is used to cleave the end of the molecule and insert a double stranded strand of oligonucleotides at this terminus.
  • the RNA is degraded and the cDNA containing both 3′ and 5′ primer sequences is amplified through PCR.
  • Random priming An alternative method for creating the second strand of cDNA is the use of a random primer.
  • the first strand cDNA is contacted by a primer that has a random sequence that allows a DNA dependent DNA polymerase to extend this primer in the opposite direction of first strand cDNA creating a second strand of cDNA.
  • the random primer contains a second primer sequence at the 5′ end of the primer, then this second strand reaction encodes an amplification primer at the 5′ end of the second strand molecule. In this way, the second strand molecule contains both and 3′ and 5′ primer sequence that can be used for PCR amplification.
  • T7 amplification primer As an alternative to encoding a second primer sequence in the first strand molecule of the cDNA, this molecule can be amplified using 3SR [22], NASBA [23, 24], TMA amplification. In this arrangement, a sequence allows a specific enzyme to create multiple copies of the first strand cDNA with having a complimentary second strand. Having created many copies of RNA using T7 RNA polymerase, this molecule is converted to cDNA. These amplified sequences are then used to create a sequencing library using a variety of methods.
  • the released RNA/DNA hybrid is first digested with RNaseH, then subjected to the ligation protocol to attach a 3′ handle on the complimentary strand that contains the necessary sequence to amplify the various DNA regions corresponding the regions of the tissue section that was mated to the array.
  • the primer on the high-density surface is covalently bound, but is synthesized in the reverse direction from the 5′ at the surface of the array to the 3′ terminus to provide a covalently bound primer structure with the 3′ end exposed to enable direct priming and the formation of a complimentary copy of the template from the sample.
  • Methods for the arraying such molecules with the 3′ end exposed are well known. These methods typically utilize a robotically deposited spot [25, 26].
  • oligonucleotide array is deposited using a non-contact or contact printer which creates an array of DNA spots with a 60-300 diameter feature that are separated center to center by approximately 1-2 ⁇ distance of the spot size.
  • the use of these relatively large features, compared to the cells in the tissue (around 10-30 microns) may result in several cells being present in each DNA spot, and leaves relatively large gaps between each area that is interrogated.
  • the surface bound primers may contain a specific sequence or sequences in the 5′ end to allow a restriction enzyme, endonuclease or exonuclease to cleave this extended primer from the array surface after creating a complimentary copy of the sample template nucleic acid molecule.
  • the primers may be linked to the surface using a reversible bond, such as a disulfide or any other covalent or ionic bond that can be undone or otherwise cleaved.
  • the arrays may be fabricated leaving a 3′ end exposed upon the conductive layer so as to create a high density array of primers which can form a primer:sample template complimentary primer pair.
  • the templates are directed to the surface of the array under an active force, such as electrophoresis [27, 28, 29].
  • the samples can either be cleaved from the surface to be prepared into a library for downstream sequencing analysis or alternatively used to perform in situ sequencing by synthesis analysis.
  • sequencing approaches can be integrated in the device for sample preparation to perform integrated end to end analysis of the tissue section to provide spatially and location specific arrangements of genetic elements within the tissue of origin.
  • the assay has several significant advantages over other molecular diagnostic assays. These include the following:
  • all genes in a particular site can be interrogated and also referenced back to the cell of origin.
  • all proteins can be analyzed in the sample.
  • Methods for the interrogation of proteins in tissues are well established using several molecular approaches to bind a macromolecule such as an antibody or aptamer to the protein within the sample.
  • the macromolecular reagent used to bind this sample bound protein is modified to include a nucleic acid sequence tag [30]. Using these sequence tagged reagents, the tissue can then be used in a similar IHC protocol to bind the reagents to the tissue.
  • sequence tags of these reagents can be transferred to the barcode oligonucleotide array for complimentary copying, amplification, and sequencing.
  • the use of enzymes to digest the proteins becomes important, as to properly form a hybrid pair the sequence tag should be released from the protein recognition reagent.
  • the expressed genes, gene modifications, or sequence tagged proteins can be annotated to a specific location of a cell in a sample.
  • the gene and proteins detected from the array can be recapitulated with the original image of the tissue section or cell aggregate sample. Combining the high resolution genomic analysis of features that are smaller than the cells of interest provides the ability to interrogate most, if not all cells, within the entire tissue section. Alternatively, the use of tiled barcodes can be used to interrogate only specific areas of choice.
  • two barcode sequences are used on the first strand cDNA primer.
  • one serves as the regional barcode sequence
  • the second cell barcode can be used to code for specific sub region or a specific cell within tissue.
  • the barcodes can be used in combination during a series of enrichment PCR reactions as the regional primer will enrich for a group of cells, whereas the cell barcode can be used to amplify the genes coordinated with a specific cell.
  • the barcodes can used be in combination, during a first enrichment PCR reactions, as the regional primer for a group of cells, whereas the cell barcode can be used to detect, through sequencing analysis, the genes coordinated with a specific cell. This is particularly useful as the number of surface bound barcoded primers using the high-density array will produce more sequencing reads that is capable of being effectively read out during the sequencing of the cellular material.
  • the array may contain roughly 500,000 to six million attached barcode oligonucleotide primers, the ability to sequence all of these cDNAs will provide low sequencing depth.
  • current sequencing flow cells contain enough sequencing depth to provide approximately 400,000,000 reads per flow cell, this only provides the ability to analyze approximately 1000-2000 cells, with about 200,000 to 400,000 thousand reads per cell.
  • each sequencing reaction can be PCR enriched separately and run in a distinct sequencing flow cell, providing the ability to analyze all cells in a particular tissue sample. This process allows high depth sequencing a few cells, or alternatively low depth sequencing of a high number of cells. The depth of sequencing is of course dependent on the experimental question.
  • the ability to discriminate cells based on phenotype from gene expression can be accomplished using a relatively low number of reads/cell or sequencing depth.
  • the disclosed method can also confirm phenotypic differences by detecting directly the expression of protein.
  • the system allows detection of these gene modifications in samples that have been stored or preserved for long periods of time.
  • One of the hallmark events in the development of cancers is the modification of a parent gene in the genome.
  • These modifications can take a variety of forms including: a single base mutation, a re-arrangement, a deletion, or amplification of a given gene.
  • a modification of the workflow can be employed to detect these alterations in the genome.
  • a specific barcoded primer can be designed to form a complimentary hybrid pair with a specific sequence in the genome.
  • the DNA must be released from the tissue in a size range that is convenient to create an encoded copy that can form a complimentary base pair with the surface bound oligonucleotide primer.
  • Several methods of creating the required size of DNA have been developed including shearing the DNA, sonication the DNA, and fragmenting the DNA by using an enzyme.
  • One method of creating a certain size range of template DNA is the use of a restriction enzyme or endonuclease. The use of these enzymes creates double strand breaks in the DNA and depending on the amount of enzyme and the duration of the incubation can create DNA fragments in the size range from approximately 200 bases to 2000 bases. This fragmented DNA can then be hybridized to the array surface, where it is then copied using a DNA dependent DNA polymerase.
  • a device may be an integrated system to allow imaging of an aggregation of cells allowing transfer of the nucleic acids in the sample to a high density oligonucleotide array, and to actively move the templates from the sample to the array.
  • the device contains a through hole at the top of the device to supply reagents and access to an electrode to form an electrical potential between the through hole, and the array surface which contains a conductive layer.
  • the device further contains both input and outlet channels to allow the introduction of reagents for additional reactions and washing steps to facilitate sample preparation of the transferred templates that are hybridized on the array surface.
  • the top component of the device is a compression frame that allows samples to be deposited and compressed on to the array surface.
  • FIG. 2 An exploded drawing of the device ( FIG. 2 ) shows a detailed description of the device construction. From the bottom up the device contains a base layer that contains a high-density array of barcoded oligonucleotides.
  • the structure of the aforementioned oligonucleotides may have several sections as previously described. In this embodiment, the oligonucleotide attached to the array surface has 6 sections.
  • the barcode array is formed or deposited using array based oligonucleotide synthesis in such a way the array is tiled ( FIG. 4 ) to enable selection of the regions of interest for further analysis.
  • each oligonucleotide probe on the surface has two barcodes ( FIG. 3 ), one that is specific to the individual probe (the cell barcode) on the surface and a second barcode that indicates a region or a selection or group of individual cell barcodes.
  • the high-density oligonucleotide array may be housed in a chamber created by several layers that are assembled upon the substrate used for the barcode array. These layers typically will include a channel layer, that will be fabricated from an adhesive, and a fluidic interconnect that will be formed from an extruded or thermoplastic resin.
  • the components may include a porous substrate such as porous glass, optionally an adhesive layer to secure this material to the compression frame, and gasket material to allow the channel to be sealed during sample dissolution.
  • a porous substrate such as porous glass
  • an adhesive layer to secure this material to the compression frame
  • gasket material to allow the channel to be sealed during sample dissolution.
  • the sample placed directly upon the porous substrate can be processed to remove, if necessary, the paraffin used to embed the sample. Having removed the paraffin, the sample upon the porous substrate is combined with the compression frame ( FIG. 5C ) and inserted into the device to place the sample in intimate contact with the barcode array ( FIG. 5D ).
  • the sample can be further processed to release the template nucleic acids to allow complimentary base pairing with the barcode oligonucleotides on the high-density array surface ( FIG. 6 ).
  • the sample With the sample affixed to the substrate (as shown, the substrate in FIG. 6 to which the cells are mounted is porous—but a porous substrate is not a requirement) and combined with the compression frame ( FIG. 5 ), the sample can now be placed in direct contact (or fluid communication) with the array surface ( FIG. 6 ) and come into close contact (or fluid communication) with the arrayed oligonucleotides. With these cells in close contact (or fluid communication), the sample can now be processed.
  • Reagents may be conducted through a porous substrate so as to come in contact with the sample, though this is not a requirement, as reagents may be introduced to the sample in other ways besides the “back side” of the sample if the sample is mounter on a porous substrate.
  • a non-porous layer in the disclosed technology; cells may be attached to a non-porous layer and then be processed so as to liberate nucleic acids.
  • they can be introduced through an alternative inlet, e.g., a channel in the same plane of the sample.
  • This channel height can be controlled through the design of the device, to both minimize the distance between the sample and the array, while also providing an appropriate channel height to introduce reagents.
  • a tissue sample may be positioned from about 1 to about 50 micrometers from the array, allowing reagents to be introduced in the space between the sample and the array.
  • one may control the flow of reagents so as to ensure diffusion and/or to ensure that fluid movement is minimized during the active nucleic acid transfer step.
  • a cellular sample may be attached to a cellular support substrate located where the “porous substrate” is shown in FIG. 2 ; the cellular support substrate need not be porous.
  • one or more reagents may be introduced by way of the “input inlet” shown in FIG. 1 , and excess material may be removed by way of the “output outlet” shown in FIG. 1 .
  • reagents need not necessarily be introduced by way of the “back” of the substrate on which cells are disposed; instead, reagents (e.g., lysing reagents) may be introduced into the space between the cell sample and the array facing the cells.
  • the reagents need not necessarily be introduced into a side of a device; reagents may be introduced by way of an inlet formed essentially anywhere in a device, e.g., by way of an inlet formed in a substrate the supports the array, by way of an inlet formed in the side of a chamber that defines a volume between a cell sample and an array, or an inlet formed elsewhere.
  • the reagents in this step digest the tissue, effectively releasing the nucleic acids from the tissue. These nucleic acids are then conducted from the sample to the array surface using an active force and begin to hybridize with the array.
  • a capillary plate or other porous medium may be disposed between the sample and the array so as to maintain linear motion of material between the sample and the array and minimize “drift” or sideways motion of material that is being communicated from the sample toward the array.
  • One active force that is convenient for methods of translocating charged molecules from one location to another is the use of electrical potential or electrophoresis. This may be done by creating a uniform conductive layer on the substrate used to deposit the oligonucleotide array ( FIG. 7 ). Having the sample in contact with the array and in the presence of the aqueous reagents used to process the sample provides the ability to create a potential through the assembled device. In this case a potential will conduct the sample template toward the oligonucleotide array ( FIG. 7C ).
  • the array surface may include a near-contiguous layer of oligonucleotide sequences that differ in several portions of the sequence.
  • the primers on the array however a critical feature is having the 3′ end of the oligonucleotide exposed to allow the primer to extend when having formed a complimentary base pair.
  • oligonucleotides On the array are two sets of oligonucleotides, one oligonucleotide set that is fabricated on the array, with the 5′ end exposed, and a second barcoded set of primers, that forms a complimentary pair with the surface tethered oligonucleotides.
  • this base paired double stranded molecule that has one strand that has its 3′ end exposed, serves as a spatially located set of primers that can produce a complimentary copy of the each template in the sample provided it can hybridize.
  • a range of reactions can be conducted.
  • a reverse transcription reaction is often used to create cDNA that can be further amplified. After the complimentary copy of the RNA, or the cDNA, is made, these templates can simply be denatured from the surface of the array.
  • RNA, DNA, and proteins for analysis may be prepared as well, however this is completely dependent on the target analyte selected for analysis.
  • the system can prepare RNA, DNA, and proteins for analysis. DNA for example would not require a reverse transcription step, only the use of DNA dependent DNA polymerase.
  • step A an oligonucleotide having a known sequence, is applied, affixed, or synthesized in a specific and known location on a surface (array surface).
  • step B of FIG. 9 a primer that has several components, is hybridized to the surface-bound oligonucleotide, with the Bc1 sequence referencing or otherwise being correlated to the Ac1 sequence, so as to be able to locate the origin of the primer after creating a complimentary copy of the sample template, amplification of this copy, and sequencing analysis.
  • a primer may contain several sequences, and may contain more or less depending on the requirements for selection of the regions and cells for downstream analysis.
  • the primer will always contain a 3′ end that allows the extension of the primer in the presence of a polymerase.
  • the template molecule hybridizes to the extension primer (EP1) sequence, which can be extended in either an RNA or DNA dependent DNA polymerization.
  • EP1 extension primer
  • one or several steps can be employed to add an adapter on the 3′ end of the cDNA molecule. As discussed, there are several methods to add this adaptor, including but not limited to ligation, template switching, and the use of random PCR primers.
  • second strand synthesis can then occur, followed by amplification of the cDNA and or inclusion of further adaptors for sequencing based analysis.
  • further steps may be required to prepare a library for sequencing based analysis.
  • the BC1 and (optional BC2) sequences are suitably preserved in the amplicon that is eventually sequenced.
  • the data is converted back to a file that can be analyzed to associate the gene of interest and the location barcode with the cell or region of interest.
  • the data can be handled in several different manners.
  • the device is controlled by an instrument that can additionally perform fluid and thermal control while conducting various reagents and buffers to the device to enable the steps required for high resolution spatial genomic mapping.
  • the device instrument further allows imaging of the sample after placed into the device.
  • Optical communication of photons emitted from the device therein can be accomplished using an optical coupling situated between the assay device and device.
  • Suitable optical couplings include an optical waveguide, a lens or series of lenses, an optical fiber bundle, a transparent (e.g. glass or plastic) rod, a fiber plate, an aperture, a filter set, or any combination thereof.
  • the optical coupling includes a series of lenses including a series of filters.
  • Suitable lenses provide an optical magnification of 1 ⁇ to 100 ⁇ , and most preferably 10 ⁇ -40 ⁇ .
  • Suitable filters can block all or a portion of excitation light and pass all or a portion of emitted light.
  • the illuminator and detection optical paths are suitably coincident between a dichroic filter and the assay device.
  • Suitable illuminators can be adjacently secured to the sample preparation device to provide a source of excitation to the analyte molecules situated in the assay device.
  • Typical illumination trains include one or more of the following: emission source, apertures, filter sets, and focusing optics.
  • Suitable emission sources can be secured to a filter block and the light can be modified by an aperture.
  • Suitable illumination sources typically include a light emitting diode (LED), a laser, an incandescent light source, a fluorescent light source, an electroluminescent light source, a plasma light source, a laser, or any combination thereof.
  • the illuminator includes an LED or laser. Suitable LEDs or lasers are capable of emitting any of a variety of light wavelengths. Any variety of two or more light sources can be combined to provide further wavelength distribution to mix colors. For example, light sources can be combined using a split fiber optic bundle connected to two LEDs, lasers, or any combination thereof.
  • Suitable detectors are typically adjacent or optically connected to the device.
  • Typical detection trains can include an excitation source (from analytes or molecules), apertures, filter sets, collection optics, and a suitable photon detector.
  • the selection of the photon detector used allows for different types of detection. Examples of suitable photon detectors include photomultiplier tubes (PMT), avalanche photodiodes (APD), and charge coupled devices (CCD).
  • the TEC be in close contact with the assay device so that the heating or cooling is achieved in a short period of time.
  • the controller is capable of regulating the temperature of the device in the range of from about ⁇ 25 deg. C to about 150 deg. C. Controlling the temperature of the device is typically used for thermal reduction in device separations, and precise thermal control during nucleic acid interactions and hybridizations.
  • Control of temperature in distinct regions of the assay device assists in performing and optimizing chemical reactions. For example, between 1-1000 distinct regions of the assay device can be controlled in this capacity. More typically, the number of temperature control regions is in the range of from about 1 to about 10. Control of the temperature can be achieved by using thermistors, which measure the temperature by changes in voltage.
  • the system further includes pressure control of the assay device.
  • Suitable pressure controllers can include: syringe pumps, electrokinetic pumps, fluid flow pressure restrictions, or any combination thereof
  • the pressure control can be directly connected with the device.
  • the pressure can also be controlled through the pneumatic control of a distinct region.
  • the pressure control is capable of regulating the pressure from 0-32 atmospheres or 0-300 psi.
  • methods that include providing a system of the present invention, thermally controlling a fluidic device, and detecting at least one fluorescent molecule.
  • the detection systems of the present invention need not only control the temperature, but may also control other variables such as pressure, dynamic flow, and buffer combinations on a single probe. As stated above, the temperature is controlled during hybridization, but the other factors may also be adjusted to optimize hybridization kinetics. Further optimization by one of ordinary skill can be undertaken to minimize reagent use. Working in microfluidic systems helps reduce the amount of reagent used, as compared to standard flat glass arrays and PCR assays. The devices and methods of the present invention make it possible to screen, capture and detect probes in series for optimal conditions.
  • NA nucleic acid
  • a nucleic acid (“NA”) sample is first denatured to open up its strands in preparation for hybridization. Preventing non-specific hybridization utilizing tight control of the temperature, e.g., a change of 10 degrees Celsius will allow a 1 base mismatch in a 20-base probe. As the detection probe is increased in length, the temperature difference for a mismatch decreases, and the chance of nonspecific hybridization increases.
  • NA hybridization can be done with an array-bound probe and a sample.
  • the probe can be a set length oligonucleotide or chain of NA bases. Typically, the probe length is 12-1000 bases long. Typically, as many as 6,000,000 probes are used for sample template hybrid capture.
  • the sample is taken from a biological specimen including but not limited to: viruses, bacteria, tissue, blood, animal cells, and plant matter.
  • the length of the sample NA is typically not tightly controlled and may vary from single base pairs up to full length gene sequences. Through sample preparation some control of the NA is possible, often this is a range of 20-10,000 bases.
  • sample is longer than 500 bases long, longer incubation times may be required to allow denature and hybridization of the sample template and surface bound primer. This will only be the case for double stranded targets and does not affect the hybridization of single stranded RNA templates and barcoded DNA sample templates.
  • Probes can be used in two possible ways, first in solution where they interact with the sample NA through diffusion and are dispersed throughout the sample. Secondly, probes can be attached to a fixed surface where the sample NA is allowed to come in contact with the probe. In either case, the temperature of the probe and sample NA in solution is carefully controlled to provide hybridization while limiting non-specific template:primer or primer:primer interaction.
  • the inventive systems of the present invention can be used for optimization of either fixed of free floating probes. Different probes can open up at different temperatures, which is dependent on the bases associated with the probe and anything that is connected with the probe, such as chemistry for connecting to a fixed surface or fluorescent probes. The temperature for conducting proper hybridization is preferably determined.
  • Device electrophoresis can be performed by applying a voltage or current from an anode to cathode that are connected via a microfluidic channel or device.
  • This voltage potential results in migration of charged species or colloidal particles, which migration causes the movement of ions through the chamber.
  • the speed of the migration i.e., separation, depends on the current across the separation chamber. As the current is increased, the separation takes a shorter time. The limiting factor for separation velocity is the resulting joule heating generated with high current flows. As heat is generated in the device, bubbles form at high temperature points. The bubbles act as dielectrics and force the current through a smaller path which generates higher temperatures. By cooling the separation chamber, heat generated during the separation is removed and higher voltages can be used, resulting in faster separations.
  • Device cooling also increases resolution of the separation.
  • the resolution of the sample is limited by the diffusion of the sample.
  • the sample will naturally diffuse in the chamber.
  • Temperature control for electrophoresis can also allow the use of alternate sieving materials, especially materials that would be affected by fluctuations in temperature. Specific control of distinct regions can also allow some sample preparation to be performed in the separation channel. For example, in DNA separations, the sample can be denatured just before entering the sieving matrix.
  • the detection systems of the present invention allow for new and novel techniques in separation technologies.
  • Embodiment 1 A system, comprising: a plurality of base polynucleotides disposed on an amplification substrate; an optionally porous cellular support substrate, the optionally porous cellular support substrate and the amplification substrate defining a chamber therebetween; an inlet, the inlet optionally comprising an aperture formed in the cover, the inlet optionally placing the optionally porous layer into fluid communication with the environment exterior to the optionally porous cellular support substrate.
  • Embodiment 2 The system of embodiment 1, further comprising a frame disposed between the amplification substrate and the optionally porous cellular support substrate, the frame defining the chamber between the optionally porous cellular support substrate and the amplification substrate.
  • Embodiment 3 The system of any of embodiments 1-2, wherein one or both of the substrate and the optionally porous cellular support substrate is a conductive material.
  • Embodiment 4 The system of any of embodiments 1-3, further comprising a voltage source configured to supply an electrical gradient between the optionally porous cellular support substrate and the substrate, the electrical gradient being configured so as to translocate nucleic acids in a direction essentially perpendicular to the optionally porous cellular support substrate and toward the amplification substrate.
  • a voltage source configured to supply an electrical gradient between the optionally porous cellular support substrate and the substrate, the electrical gradient being configured so as to translocate nucleic acids in a direction essentially perpendicular to the optionally porous cellular support substrate and toward the amplification substrate.
  • Embodiment 5 The system of any of embodiments 1-4, further comprising an imager in optical communication with the chamber.
  • Embodiment 6 The system of any of embodiments 1-5, further comprising a source of reagents in fluid communication with the inlet.
  • Embodiment 7 The system of any of embodiments 1-6, wherein the plurality of base polynucleotides is disposed on two or more discrete regions of the amplification substrate.
  • Embodiment 8 The system of any of embodiments 1-7, wherein at least some of the base polynucleotides of the amplification substrate are bound to amplification primers.
  • Embodiment 9 The system of embodiment 8, wherein at least some of the amplification primers comprise one or more of (1) a nucleic acid sequence complementary to one or more base polynucleotides of the amplification substrate, (2) a nucleic acid sequence associated with the location of the amplification primer on the amplification substrate, (3) a nucleic acid sequence specific to that amplification primer, and (4) a nucleic acid sequence complementary to a target nucleic acid sequence in a sample.
  • the amplification primers comprise one or more of (1) a nucleic acid sequence complementary to one or more base polynucleotides of the amplification substrate, (2) a nucleic acid sequence associated with the location of the amplification primer on the amplification substrate, (3) a nucleic acid sequence specific to that amplification primer, and (4) a nucleic acid sequence complementary to a target nucleic acid sequence in a sample.
  • Embodiment 10 The system of embodiment 9, wherein at least some of the amplification primers comprise at least two nucleic acid sequences associated with the location of the amplification primer on the amplification substrate.
  • Embodiment 11 The system of any of embodiments 9-10, wherein at least some of the amplification primers comprise at least (1) a nucleic acid sequence complementary to one or more base polynucleotides of the amplification substrate, (2) a nucleic acid sequence associated with the location of the amplification primer on the amplification substrate, (3) a nucleic acid sequence specific to that amplification primer, and (4) a nucleic acid sequence complementary to a target nucleic acid sequence in a sample.
  • Embodiment 12 A method, comprising: liberating nucleic acids from a cellular sample affixed to an optionally porous cellular support substrate, the cellular sample being capable of fluid communication with an amplification substrate bearing a plurality of amplification primers; translocating the liberated nucleic acids in a direction essentially perpendicular from the optionally porous cellular support substrate under such conditions that the liberated nucleic acids hybridize to the plurality of amplification primers, the liberated nucleic acids optionally being communicated in the direction of the plurality of amplification primers through the pores of a porous material; and amplifying the nucleic acids so as to give rise to amplification products.
  • Embodiment 13 The method of embodiment 12, wherein the translocating is effected by a voltage gradient.
  • Embodiment 14 The method of any of embodiments 12-13, wherein the liberating is effected by one or more reagents contacted to a porous substrate in fluid communication with the cellular sample.
  • Embodiment 15 The method of embodiment 14, wherein the substrate is a porous substrate.
  • Embodiment 16 The method of any of embodiments 12-15, wherein the cellular sample contacts the amplification substrate.
  • Embodiment 17 The method of any of embodiments 12-16, further comprising collecting the amplification products.
  • Embodiment 18 The method of any of embodiments 12-17, wherein at least some of the amplification primers comprise one or more of (1) a nucleic acid sequence complementary to one or more base polynucleotides of the amplification substrate, (2) a nucleic acid sequence associated with the location of the amplification primer on the amplification substrate, (3) a nucleic acid sequence specific to that amplification primer, and (4) a nucleic acid sequence complementary to a target nucleic acid sequence in a sample.
  • the amplification primers comprise one or more of (1) a nucleic acid sequence complementary to one or more base polynucleotides of the amplification substrate, (2) a nucleic acid sequence associated with the location of the amplification primer on the amplification substrate, (3) a nucleic acid sequence specific to that amplification primer, and (4) a nucleic acid sequence complementary to a target nucleic acid sequence in a sample.
  • Embodiment 19 The method of any of embodiments 12-18, further comprising associating an amplification product with a location within the cellular sample.
  • Embodiment 20 The method of any of embodiments 12-19, further comprising associating an amplification product with an amplification primer.
  • Embodiment 21 The method of any of embodiments 12-20, further comprising affixing the cellular sample to the optionally porous cellular support substrate.
  • Embodiment 22 The method of any of embodiments 12-21, further comprising removal of one or more fixatives from the cellular sample.
  • Embodiment 23 The method of any of embodiments 12-22, further comprising hybridizing the amplification primers to base polynucleotides affixed to the amplification substrate.
  • Embodiment 24 A method, comprising: liberating nucleic acids from a cellular sample affixed to an optionally porous cellular support substrate, the cellular sample overlying a plurality of amplification primers; translocating the nucleic acids in a direction perpendicular from the optionally porous cellular support substrate under such conditions that the nucleic acids hybridize to at least some of the plurality of amplification primers, the liberated nucleic acids optionally being communicated in the direction of the plurality of amplification primers through the pores of a porous material; amplifying the nucleic acids so as to give rise to amplification products; and associating at least some of the amplification products with locations within the cellular sample.
  • Embodiment 25 The method of embodiment 24, wherein the liberating is effected by one or more reagents contacted to a porous substrate in fluid communication with the cellular sample.
  • Embodiment 26 The method of embodiment 25, wherein the porous substrate is the optionally porous cellular support substrate.
  • Embodiment 27 A sample preparation system for high resolution spatial genetic analysis, comprising: (a) a sample preparation module material capable of attaching a cellular sample to an optionally porous cellular support substrate that allows imaging of the tissue or cell aggregate or tissue section sample on one side, and provides the ability to deliver reagents to the sample; (b) a sample preparation module material that allows chemical fixation of a cellular sample to occur on the surface of the optionally porous cellular support substrate; (c) a sample preparation module that is chemically inert to non-polar solvents; (d) a sample preparation module capable of treating the cellular sample treated with reagents to label proteins with nucleic acid sequenced tagged antibodies, aptamers or any other ligand to bind to a specific protein with a cell in the sample; (e) a device capable of imaging of the cellular sample in close proximity to an array of oligonucleotides to coordinate the tissue sample location with each oligonucleotide element on the array; (f) a sample preparation
  • Embodiment 28 A fluidic device to perform high resolution spatial genomic analysis, comprising: a sample preparation module, a series of fluidic channels and an array of oligonucleotides disposed on a conductive surface within the device so as to allow for one or more of sample addition, fixation, paraffin removal, incubation, sample imaging, active control target of sample nucleic acid templates, and multistep molecular biology reactions to effect sample preparation, hybridization, reverse transcription and first strand cDNA synthesis of sample templates with the device.
  • Embodiment 29 The device of embodiment 28, further comprising sample preparation module material that effects attaching the sample to a cellular support substrate, the cellular support substrate optionally being porous, and the material further allowing imaging of the tissue or cell aggregate or tissue section sample on one side of the optionally porous cellular support membrane and providing the ability to deliver reagents to the sample.
  • Embodiment 30 The device of any of embodiments 28-29, wherein the sample preparation module material that allows the attaching to occur resides on the conductive surface.
  • Embodiment 31 The device of any of embodiments 28-30, wherein the sample preparation module is chemically inert to non-polar solvents.
  • Embodiment 32 The device of any of embodiments 28-31, wherein the sample preparation module allows the sample to be treated with reagents to label proteins with nucleic acid sequenced tagged antibodies, aptamers or any other ligand to bind to a specific protein with a cell in the sample.
  • Embodiment 33 The device of any of embodiments 28-32, wherein the device allows for an image of the combined sample in close proximity to an array of oligonucleotides to coordinate the tissue sample location with each oligonucleotide element on the array.
  • Embodiment 34 The device of any of embodiments 28-33, wherein the sample preparation module seals the integrated device so as to prevent lateral fluid flow during migration of the target nucleic acids and so as to allow controlled lateral fluid flow over a bar-coded array of oligonucleotides.
  • Embodiment 35 The device of any of embodiments 28-34, further comprising a module whereby samples are digested with a proteolytic enzyme, including but not limited to proteinase or protease to release one or more sample templates.
  • a proteolytic enzyme including but not limited to proteinase or protease to release one or more sample templates.
  • Embodiment 36 The device of any of embodiments 28-35, further comprising a module that effects migration of the charged nucleic acid templates to the array surface.
  • Embodiment 37 The device of any of embodiments 28-36, further comprising a module whereby sample templates are migrated under the control of electrophoresis.
  • Embodiment 38 The device of any of embodiments 28-37, further comprising a process where cellular samples templates are migrated under the control of directional flow generated by pressure of electrokinetic flow.
  • Embodiment 39 The device of embodiment 38, wherein the areal density of probe elements in the array is equal or higher than the density of the cells which reside on the cellular support substrate.
  • Embodiment 40 The device of any of embodiments 28-39, wherein the array comprises from about 3000 to about 2,000,000 oligonucleotide probe array elements.
  • Embodiment 41 The device of any of embodiments 28-40, wherein the array comprises a set of oligonucleotide probe elements comprising first array sequences that in combination with a set of barcode sequences form a hybrid pair with the 3′ end exposed that serves as a hybridization and primer element on the array.
  • Embodiment 42 The device of any of embodiments 28-41, wherein the array comprises a set of first array sequences that are synthesized in high density in reverse order with the 3′ end exposed that serves as a hybridization and primer element on the array.
  • Embodiment 43 The device of any of embodiments 28-42, wherein the array comprises a set of array sequences that contain a primer sequence on the 3′ terminus, which may include an oligo dT sequence, a specific primer sequence or a random sequence.
  • Embodiment 44 The device of any of embodiments 28-43, further comprising a plurality of oligonucleotide probes that comprise a sequence that allow accurate quantification of the copy number of sample template molecules.
  • Embodiment 45 The device of any of embodiments 28-44, further comprising a plurality of probe elements associated with the location, presence, or both of a genetic element specific to a cell, a cell region, regions or the entire array.
  • Embodiment 46 The device of any of embodiments 28-45, further comprising a barcode array that comprises a number of distinct barcode sequences that allows amplification or enrichment of a selected area on the array.
  • Embodiment 47 The device of any of embodiments 28-46, the device being configured such that one or more reactions can be conducted on the array surface, the one or more reactions comprising the use of one or more of a RNA or DNA dependent DNA polymerase, a ligase, exonuclease, or endonuclease so as to provide the ability to create a barcoded first strand cDNA.
  • Embodiment 48 The device of any of embodiments 28-47, the device being configured to allow the first strand reaction products to be released from the surface using a restriction endonuclease or temperature to release the first strand cDNA.
  • Embodiment 49 The device of any of embodiments 28-48, the device being configured so as to allow a process that provides a sample that can be transformed into a sequencing library with known barcode sequences which can be split into individual reactions to provide a sample that is sequenced at high read depth using next generation sequencing.
  • Embodiment 50 A method for spatially resolving protein and/or nucleic acids from biological samples, comprising the steps of: mounting a sample to a porous surface; hydrating the sample; placing the sample into fluid communication with a second surface that having a barcode disposed thereon and the second surface being electrically conductive; obtaining positional information regarding the sample relative to the barcode array; digesting the sample so as to release nucleic acid targets; translocating the targets to the barcode array of the second surface so as to effect hybridization; effecting sequencing of the hybridized targets; correlating results of the sequencing so as to positionally resolve the location within the sample from which one or more targets originated.
  • Embodiment 51 The method of embodiment 50, wherein the sample is one or more of a cellular monolayer and a formalin-fixed paraffin embedded sample.
  • Embodiment 52 The method of any of embodiments 50-51, wherein the barcode array is (a) permanently fixed to the second surface; or (b) releasable from the second surface by endonuclease activity or temperature.
  • Embodiment 53 The method of any of embodiments 50-52, wherein the number of array elements is at least 3,000, and preferably at least 20,000.
  • Embodiment 54 The method of any of embodiments 50-53, wherein the translocating is effected by electrophoresis.
  • Embodiment 55 The method of any of embodiments 50-54, wherein the translocation is electrokinetically induced.
  • probes comprise one or more of (a) a sequence that allows for quantification of the copy number of sample template and (b) a sequence that allows for enrichment of a specific area of the array.
  • Embodiment 57 The method of any of embodiments 50-56, further comprising performing one or more reactions on the array surface, one or more of the reactions includes the use of a RNA or DNA dependent DNA polymerase, a ligase, exonuclease, endonuclease to provide the ability to create a barcoded first strand cDNA.
  • a cellular sample (e.g., a cellular monolayer, an FFPE sample, or other sample) is affixed to a “front” surface of a cellular support substrate.
  • the cellular support substrate may be porous, although this is not a requirement.
  • the cellular support substrate may be conductive in nature, although this too is not a requirement.
  • reagents e.g., lysing reagents, buffers, and the like—may be introduced to the “back” surface of the cellular support substrate so as to then contact the cellular sample.
  • the reagents may be introduced by way of an aperture formed in a cover, the aperture being in fluid communication with the porous cellular support substrate.
  • the cellular support substrate (and cellular sample) may be disposed across from an amplification substrate, which amplification substrate may comprise an array of oligonucleotide probes, as shown in one or more of FIGS. 3, 4, 8, and 9 .
  • the amplification substrate may be conductive in nature, as shown in FIG. 1 .
  • a device may include an input inlet and, optionally, an output outlet. The input inlet may allow introduction of reagents, washes, and the like, and the output outlet may allow for the output of washes, buffers, excess reagents, and even reaction products.
  • a device according to the present disclosure may include a reagent electrode inlet, which may be used to introduce reagents to a cellular sample; this is particularly suitable when the cellular sample is fixed to a porous cellular support substrate.
  • FIG. 2 provides an exploded view of a device according to the present disclosure.
  • a device may include a high density barcode array (of oligonucleotides); such arrays are described elsewhere herein in additional detail.
  • the barcode array may be formed on a substrate material, which substrate material may be conductive.
  • a device may include a channel layer (optionally adhesive in nature). As shown, the channel layer may define tapered regions and/or regions of constant cross section.
  • an interconnect may include one or more apertures formed therein, which apertures may be used as inlets and/or outlets as shown in FIG. 1 .
  • a device may include a porous substrate useful for cellular support, although this substrate need not necessarily be porous, although a porous substrate is considered especially suitable.
  • a cellular sample may be fixed to the (optionally) porous substrate.
  • the device may include an adhesive layer, a gasket (which may be characterized as an O-ring), an additional adhesive layer, and even a compression frame.
  • the compression frame (sometimes termed “cover”) may include an aperture formed therethrough, which aperture may place a cellular sample fixed to a porous layer into fluid communication with the environment exterior to the compression frame.
  • a device may also include a porous material (not shown) disposed between the optionally porous cellular support substrate and the substrate that comprises the barcode array.
  • This porous material may be considered a “guiding material” and may comprise a plurality of channels that allow for transport of material from a cellular sample on the cellular support substrate directly toward the array, with the pores acting to minimize diffusion and/or movement of material in directions that are not directly toward the array.
  • the porous material may act to enhance transport of material (e.g., liberated nucleic acids) in a direction perpendicular from the cellular support substrate towards the barcode array.
  • porous material may be characterized as having channels formed therein.
  • Capillary sheets and the like are considered suitable porous (or “guiding”) materials; a guiding material suitably has discrete pores or channels that are parallel to one another and run perpendicular to the surface(s) of the material.
  • FIG. 5 illustrates a device according to the present disclosure.
  • FIG. 5A illustrates a porous cellular support substrate engaged with an O-ring sealing gasket
  • FIG. 5B illustrates a compression frame having an inlet through hole formed therein.
  • a tissue section ( FIG. 5C ) may be fixed to the cellular support layer, and then, as shown in FIG, 5 D, the tissue section is present in the chamber defined between the various device layers shown in FIGS. 1 and 2 , the tissue section now being available for treatment by reagents, buffers, and the like that are introduced from external to the chamber.
  • FIG. 5C A tissue section
  • FIG. 7 illustrates a cutaway view of a device according to the present disclosure, illustrating (via the arrows) how material (e.g., reagents, buffers, and the like) delivered through the through-hole of the cover may then become distributed along the porous cellular support substrate and as a consequence to cells that are fixed to or otherwise associated with that substrate.
  • material e.g., reagents, buffers, and the like
  • FIG. 6 depicts, from top to bottom, an exemplary process according to the present disclosure.
  • a barcode array may comprise one or more probes according to the example of FIG. 3 .
  • a given probe may include one or more sequences that provide specific information regarding the location of the probe (e.g., the probe's relative location within the array), regarding a cellular sample (including a cell of the cellular sample) that may be associated with the probe, regarding a specific molecule (e.g., information regarding a cell, a gene, a treatment, a disease state, and the like), or even other information regarding that given probe.
  • a user can then determine a variety of location-specific characteristics of the liberated nucleic acid. (Suitable hybridization, amplification, and other steps are shown in FIGS. 4, 6, 8, and 9 .
  • a user may determine that in a tissue sample of a cross-section of a liver, a cell at locations X 1-100 , Y 1-100 may possess a certain gene of concern, whereas cells at locations X 101-1000 , Y 101-1000 do not possess that same gene of concern. This may in turn allow for an improved treatment recommendation that involves excision of tissue at only the locations where the gene of concern was present, instead of total excision of the liver.
  • a device is used to identify the transcribed genes and expressed proteins of a particular group of cells at single cell resolution from an FFPE section.
  • a user mounts a 4-20 micrometer section of tissue to a customized sample transfer slide and heats this slide for approximately 1-3 hours to attach the sample material to the slide.
  • the paraffin that surrounds the sample is removed from the transfer device.
  • the sample, now attached to the transfer device can be exposed to a variety of reagents including antibodies (which include an oligonucleotide to identify the specific antibody) to detect expressed proteins.
  • This slide is then incubated to allow hybridization of the oligo linked antibodies to the proteins on the cells within the tissue sample.
  • the transfer device is assembled with the array cartridge.
  • the assembled device is then imaged using a standard epi-fluorescent microscope.
  • Reagents to conduct the sample permeabilization and first strand cDNA production are loaded into the cartridge.
  • the user then inserts the cartridge into the instrument to conduct the automated permeabilization, template hybridization, and first strand synthesis reaction.
  • the device in a series of steps introduces the permeabilization reagents, and controls the temperature to conduct this digestion.
  • the device activates the electric field to conduct electrophoresis of the sample templates, now being liberated from the sample (including the oligonucleotides that are attached to the antibodies), to the high density array, which either contains an array of covalently linked primers (with the 3′ end exposed) or an array of 3′ attached oligonucleotides with a second complexed primer.
  • the sample templates hybridize to the array surface.
  • the array When hybridization is complete the array is washed and the array, with the hybridized templates complexed to the array, is exposed to the reagents required for reverse transcriptase. These reagents are then incubated in the chamber, which extends the primers that are hybridized to the sample templates.
  • the extended first strand cDNA products are then released from the high density array either through the use of a restriction enzyme, or denaturation or both.
  • the released first strand cDNAs are then exported to an outlet well on the cartridge, where the user removes this material by aspiration with a pipette.
  • This sample is then purified using magnetic beads, and then subjected to a ligation protocol to add the 5′ oligonucleotide to the first strand cDNA. The sample is once again purified, and prepared for enrichment.
  • the user To perform enrichment of target region, the user first returns to the sample image, and through the software system selects the regions of interest within the image. These regions of interest correspond set of barcodes which are used as primers during the enrichment process. The user then selects tis set of primer from a plate of barcode primers and combines this with the purified sample eluted from the device. The combination is then thermal cycled to amplify the regions of interest corresponding to the original image. Due to the structure of the barcode primers the product of this reaction is sequencer-ready once re-purified. Each regional barcode selected by the user may contain approximately 1000 cells.
  • Approximately 3-6 regions can be submitted to the single sequencing lane, using a standard flow cell sequencing system (e.g., IlluminaTM systems) depending on the sequencing depth required by the user.
  • a standard flow cell sequencing system e.g., IlluminaTM systems
  • the user may analyze up to 50,000 cells per sequencing run. The user re-use the sample to produce more enriched regions for sequencing, even every cell (e.g., millions of cells) in the image.
  • sequencing analysis complete the user compiles the BML or FASTQ file with the cell image to create a series of heat maps to identify the genes that variable between the cells with the region of interest. This process effectively links the cell morphology and phenotype to the underlying genetic and proteomic structure.
  • the disclosed technology may be used to identify the transcribed genes and expressed proteins of a particular group of cells at single cell resolution from a cell suspension.
  • cytospin a procedure known as “cytospin” to affix suspension cells of interest to a customized sample transfer slide.
  • the sample is then preserved using a fixation procedure, which may include paraformaldehyde, glutaldehyde, an alcohol or a combination thereof.
  • the sample, now attached to the transfer device can be exposed to a variety of reagents including antibodies (which include an oligonucleotide to identify the specific antibody) to detect expressed proteins.
  • This slide is then incubated to allow hybridization of the oligo linked antibodies to the proteins on the cells within the tissue sample.
  • the transfer device is assembled with the array cartridge.
  • the assembled device is then imaged using a standard epi-fluorescent microscope.
  • Reagents to conduct the sample permeabilization and first strand cDNA production are loaded into the cartridge.
  • the user then inserts the cartridge into the instrument to conduct the automated permeabilization, template hybridization, and first strand synthesis reaction.
  • the device in a series of steps introduces the permeabilization reagents, and controls the temperature to conduct this digestion.
  • the device activates the electric field to conduct electrophoresis of the sample templates, now being liberated from the sample (including the oligonucleotides that are attached to the antibodies), to the high density array, which either contains an array of covalently linked primers (with the 3′ end exposed) or an array of 3′ attached oligonucleotides with a second complexed primer.
  • the sample templates hybridize to the array surface.
  • the array When hybridization is complete the array is washed and the array, with the hybridized templates complexed to the array, is exposed to the reagents required for reverse transcriptase. These reagents are then incubated in the chamber, which extends the primers that are hybridized to the sample templates.
  • the extended first strand cDNA products are then released from the high density array either through the use of a restriction enzyme, or denaturation or both.
  • the released first strand cDNAs are then exported to an outlet well on the cartridge, where the user removes this material by aspiration with a pipette.
  • This sample is then purified using magnetic beads, and then subjected to a ligation protocol to add the 5′ oligonucleotide to the first strand cDNA. The sample is once again purified, and prepared for enrichment.
  • the user To perform enrichment of target region, the user first returns to the sample image, and through the software system selects the regions of interest within the image. These regions of interest correspond set of barcodes which are used as primers during the enrichment process. The user then selects tis set of primer from a plate of barcode primers and combines this with the purified sample eluted from the device. The combination is then thermal cycled to amplify the regions of interest corresponding to the original image. Due to the structure of the barcode primers the product of this reaction is sequencer-ready once re-purified. Each regional barcode selected by the user will contain approximately 1000 cells.
  • Approximately 3-6 regions can be submitted to the single sequencing lane, using a standard flow cell sequencing system (e.g., an IlluminaTM system) depending on the sequencing depth required by the user.
  • a standard flow cell sequencing system e.g., an IlluminaTM system
  • the user can analyze up to 50,000 cells per sequencing run.
  • the user re-use the sample to produce more enriched regions for sequencing, even every cell (e.g., millions of cells) in the image.
  • sequencing analysis complete the user compiles the BML of FASTQ file with the cell image to create a series of heat maps to identify the genes that variable between the cells with the region of interest. This process effectively links the cell morphology and phenotype to the underlying genetic and proteomic structure.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Clinical Laboratory Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
US16/342,758 2016-10-17 2017-10-17 High resolution spatial genomic analysis of tissues and cell aggregates Pending US20190262831A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/342,758 US20190262831A1 (en) 2016-10-17 2017-10-17 High resolution spatial genomic analysis of tissues and cell aggregates

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409265P 2016-10-17 2016-10-17
PCT/US2017/056865 WO2018075436A1 (fr) 2016-10-17 2017-10-17 Analyse génomique spatiale haute résolution de tissus et d'agrégats de cellules
US16/342,758 US20190262831A1 (en) 2016-10-17 2017-10-17 High resolution spatial genomic analysis of tissues and cell aggregates

Publications (1)

Publication Number Publication Date
US20190262831A1 true US20190262831A1 (en) 2019-08-29

Family

ID=62018841

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/342,758 Pending US20190262831A1 (en) 2016-10-17 2017-10-17 High resolution spatial genomic analysis of tissues and cell aggregates

Country Status (3)

Country Link
US (1) US20190262831A1 (fr)
EP (1) EP3526348A4 (fr)
WO (1) WO2018075436A1 (fr)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021096814A1 (fr) * 2019-11-11 2021-05-20 The Broad Institute, Inc. Évaluation spatiale et quantitative d'adn haute résolution
WO2022020728A1 (fr) * 2020-07-23 2022-01-27 10X Genomics, Inc. Systèmes et procédés permettant de détecter et d'éliminer des agrégats pour faire appel à des codes à barres associés à des cellules
US11299774B2 (en) 2015-04-10 2022-04-12 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
WO2022076603A1 (fr) * 2020-10-06 2022-04-14 Icahn School Of Medicine At Mount Sinai Systèmes et procédés destinés à des applications cliniques exposomiques
US11332790B2 (en) 2019-12-23 2022-05-17 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11407992B2 (en) 2020-06-08 2022-08-09 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11408029B2 (en) 2020-06-25 2022-08-09 10X Genomics, Inc. Spatial analysis of DNA methylation
US11434524B2 (en) 2020-06-10 2022-09-06 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
US11512308B2 (en) 2020-06-02 2022-11-29 10X Genomics, Inc. Nucleic acid library methods
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
US11535887B2 (en) 2020-04-22 2022-12-27 10X Genomics, Inc. Methods for spatial analysis using targeted RNA depletion
US11560592B2 (en) 2020-05-26 2023-01-24 10X Genomics, Inc. Method for resetting an array
WO2023004058A1 (fr) * 2021-07-23 2023-01-26 BioSkryb Genomics, Inc. Analyse spatiale d'acides nucléiques
WO2023023308A1 (fr) * 2021-08-20 2023-02-23 13.8, Inc. Systèmes et procédés de caractérisation d'emplacements d'analytes cibles dans un espace multidimensionnel
US11592447B2 (en) 2019-11-08 2023-02-28 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
US11608520B2 (en) 2020-05-22 2023-03-21 10X Genomics, Inc. Spatial analysis to detect sequence variants
US11618897B2 (en) 2020-12-21 2023-04-04 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
US11624086B2 (en) 2020-05-22 2023-04-11 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
WO2023116373A1 (fr) * 2021-12-24 2023-06-29 深圳华大生命科学研究院 Procédé de génération d'une population de molécules d'acide nucléique marquées et kit pour le procédé
US11692218B2 (en) 2020-06-02 2023-07-04 10X Genomics, Inc. Spatial transcriptomics for antigen-receptors
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11702698B2 (en) 2019-11-08 2023-07-18 10X Genomics, Inc. Enhancing specificity of analyte binding
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11739381B2 (en) 2021-03-18 2023-08-29 10X Genomics, Inc. Multiplex capture of gene and protein expression from a biological sample
US11753673B2 (en) 2021-09-01 2023-09-12 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11965213B2 (en) 2019-05-30 2024-04-23 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels
US11981958B1 (en) 2020-08-20 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using DNA capture

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2019213254A1 (fr) * 2018-05-02 2019-11-07 The General Hospital Corporation Évaluation d'abondance de macromolécules spatiales à haute résolution
EP3894585A2 (fr) 2018-12-10 2021-10-20 10X Genomics, Inc. Génération de sondes de capture pour analyse spatiale
WO2020198071A1 (fr) * 2019-03-22 2020-10-01 10X Genomics, Inc. Analyse spatiale tridimensionnelle
CA3140512A1 (fr) * 2019-05-15 2020-11-19 Bgi Shenzhen Reseau et procede de detection d'informations spatiales d'acides nucleiques
US11739327B2 (en) 2020-04-11 2023-08-29 International Business Machines Corporation Positional delivery and encoding by oligonucleotides of biological cells for single cell sequencing (POS SEQ)
US20230265491A1 (en) * 2020-05-04 2023-08-24 10X Genomics, Inc. Spatial transcriptomic transfer modes
WO2023115536A1 (fr) * 2021-12-24 2023-06-29 深圳华大生命科学研究院 Procédé de génération d'une population moléculaire d'acide nucléique marquée et kit associé

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120245053A1 (en) * 2009-12-04 2012-09-27 Hitachi, Ltd. GENE EXPRESSION ANALYSIS METHOD USING TWO DIMENSIONAL cDNA LIBRARY
US20130053256A1 (en) * 2011-08-31 2013-02-28 Life Technologies Corporation Methods, systems, computer readable media, and kits for sample identification
US20130116128A1 (en) * 2011-11-07 2013-05-09 Illumina, Inc. Integrated sequencing apparatuses and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106254D0 (en) * 2011-04-13 2011-05-25 Frisen Jonas Method and product
CN105849275B (zh) * 2013-06-25 2020-03-17 普罗格诺西斯生物科学公司 检测样品中生物靶标的空间分布的方法和系统
CA3176469A1 (fr) * 2015-07-27 2017-02-02 Illumina, Inc. Cartographie spatiale d'informations de sequence d'acide nucleique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120245053A1 (en) * 2009-12-04 2012-09-27 Hitachi, Ltd. GENE EXPRESSION ANALYSIS METHOD USING TWO DIMENSIONAL cDNA LIBRARY
US20130053256A1 (en) * 2011-08-31 2013-02-28 Life Technologies Corporation Methods, systems, computer readable media, and kits for sample identification
US20130116128A1 (en) * 2011-11-07 2013-05-09 Illumina, Inc. Integrated sequencing apparatuses and methods of use

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11299774B2 (en) 2015-04-10 2022-04-12 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11613773B2 (en) 2015-04-10 2023-03-28 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11739372B2 (en) 2015-04-10 2023-08-29 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11390912B2 (en) 2015-04-10 2022-07-19 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11753675B2 (en) 2019-01-06 2023-09-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11965213B2 (en) 2019-05-30 2024-04-23 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
US11808769B2 (en) 2019-11-08 2023-11-07 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
US11592447B2 (en) 2019-11-08 2023-02-28 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
US11702698B2 (en) 2019-11-08 2023-07-18 10X Genomics, Inc. Enhancing specificity of analyte binding
WO2021096814A1 (fr) * 2019-11-11 2021-05-20 The Broad Institute, Inc. Évaluation spatiale et quantitative d'adn haute résolution
US11795507B2 (en) 2019-12-23 2023-10-24 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11560593B2 (en) 2019-12-23 2023-01-24 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11981965B2 (en) 2019-12-23 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11505828B2 (en) 2019-12-23 2022-11-22 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11332790B2 (en) 2019-12-23 2022-05-17 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
US11773433B2 (en) 2020-04-22 2023-10-03 10X Genomics, Inc. Methods for spatial analysis using targeted RNA depletion
US11535887B2 (en) 2020-04-22 2022-12-27 10X Genomics, Inc. Methods for spatial analysis using targeted RNA depletion
US11959130B2 (en) 2020-05-22 2024-04-16 10X Genomics, Inc. Spatial analysis to detect sequence variants
US11624086B2 (en) 2020-05-22 2023-04-11 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US11608520B2 (en) 2020-05-22 2023-03-21 10X Genomics, Inc. Spatial analysis to detect sequence variants
US11866767B2 (en) 2020-05-22 2024-01-09 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US11560592B2 (en) 2020-05-26 2023-01-24 10X Genomics, Inc. Method for resetting an array
US11845979B2 (en) 2020-06-02 2023-12-19 10X Genomics, Inc. Spatial transcriptomics for antigen-receptors
US11692218B2 (en) 2020-06-02 2023-07-04 10X Genomics, Inc. Spatial transcriptomics for antigen-receptors
US11512308B2 (en) 2020-06-02 2022-11-29 10X Genomics, Inc. Nucleic acid library methods
US11859178B2 (en) 2020-06-02 2024-01-02 10X Genomics, Inc. Nucleic acid library methods
US11840687B2 (en) 2020-06-02 2023-12-12 10X Genomics, Inc. Nucleic acid library methods
US11608498B2 (en) 2020-06-02 2023-03-21 10X Genomics, Inc. Nucleic acid library methods
US11781130B2 (en) 2020-06-08 2023-10-10 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11407992B2 (en) 2020-06-08 2022-08-09 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11492612B1 (en) 2020-06-08 2022-11-08 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11624063B2 (en) 2020-06-08 2023-04-11 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11434524B2 (en) 2020-06-10 2022-09-06 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
US11661626B2 (en) 2020-06-25 2023-05-30 10X Genomics, Inc. Spatial analysis of DNA methylation
US11408029B2 (en) 2020-06-25 2022-08-09 10X Genomics, Inc. Spatial analysis of DNA methylation
US11952627B2 (en) 2020-07-06 2024-04-09 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
WO2022020728A1 (fr) * 2020-07-23 2022-01-27 10X Genomics, Inc. Systèmes et procédés permettant de détecter et d'éliminer des agrégats pour faire appel à des codes à barres associés à des cellules
US11981958B1 (en) 2020-08-20 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using DNA capture
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
WO2022076603A1 (fr) * 2020-10-06 2022-04-14 Icahn School Of Medicine At Mount Sinai Systèmes et procédés destinés à des applications cliniques exposomiques
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
US11873482B2 (en) 2020-12-21 2024-01-16 10X Genomics, Inc. Methods, compositions, and systems for spatial analysis of analytes in a biological sample
US11959076B2 (en) 2020-12-21 2024-04-16 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
US11618897B2 (en) 2020-12-21 2023-04-04 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
US11680260B2 (en) 2020-12-21 2023-06-20 10X Genomics, Inc. Methods, compositions, and systems for spatial analysis of analytes in a biological sample
US11739381B2 (en) 2021-03-18 2023-08-29 10X Genomics, Inc. Multiplex capture of gene and protein expression from a biological sample
US11970739B2 (en) 2021-03-18 2024-04-30 10X Genomics, Inc. Multiplex capture of gene and protein expression from a biological sample
WO2023004058A1 (fr) * 2021-07-23 2023-01-26 BioSkryb Genomics, Inc. Analyse spatiale d'acides nucléiques
WO2023023308A1 (fr) * 2021-08-20 2023-02-23 13.8, Inc. Systèmes et procédés de caractérisation d'emplacements d'analytes cibles dans un espace multidimensionnel
US11753673B2 (en) 2021-09-01 2023-09-12 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
US11840724B2 (en) 2021-09-01 2023-12-12 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
WO2023116373A1 (fr) * 2021-12-24 2023-06-29 深圳华大生命科学研究院 Procédé de génération d'une population de molécules d'acide nucléique marquées et kit pour le procédé

Also Published As

Publication number Publication date
EP3526348A1 (fr) 2019-08-21
EP3526348A4 (fr) 2020-06-24
WO2018075436A1 (fr) 2018-04-26

Similar Documents

Publication Publication Date Title
US20190262831A1 (en) High resolution spatial genomic analysis of tissues and cell aggregates
US20210130885A1 (en) Spatial mapping of nucleic acid sequence information
CN107580632B (zh) 用于全转录组扩增的方法和组合物
CA2975739C (fr) Procedes et compositions pour analyser des composants cellulaires
WO2020243579A1 (fr) Procédés de détection de l'hétérogénéité spatiale d'un échantillon biologique
CN113767176A (zh) 成像系统硬件
JP7019656B2 (ja) 治療薬剤の発見および分析のためのプラットフォーム
US20030054383A1 (en) Integrated systems and methods for diversity generation and screening
EP3736337B1 (fr) Encodement optique des volumes discrets en utilisant des particules optiquement codées

Legal Events

Date Code Title Description
AS Assignment

Owner name: LOCIOMICS CORPORATION, NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEST, JASON A.A.;HUKARI, KYLE;SIGNING DATES FROM 20190412 TO 20190415;REEL/FRAME:048913/0573

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

AS Assignment

Owner name: BIOSKRYB GENOMICS, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LOCIOMICS CORPORATION;REEL/FRAME:061361/0273

Effective date: 20220907

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION